Clinical Profile and Predictors of Outcome in Children with Acute Fulminant Myocarditis Receiving Intensive Care: A Single Center Experience.

Abstract

Acute myocarditis in children is associated with high morbidity and mortality, with limited data on intravenous immunoglobulin (IVIG) treatment and outcome. Our goal was to describe clinical, treatment profile, and predictors of outcome in children with acute fulminant myocarditis (AFM) receiving intensive care. Case records of 120 children with clinical diagnosis of acute myocarditis from January 2008 to December 2018 were analyzed retrospectively. AFM was seen in 89 (74.2%) children of which nearly two-thirds (54 [60.7%]) were hypotensive at admission. The median (interquartile range [IQR]) ejection fraction on echocardiography was 25 (18.5-36%). Eighty-two children (68.3%) received IVIG. Intensive care needs were mechanical ventilation ( n  = 71; 59.2%) and inotrope support ( n  = 89; 74.2%); median inotrope score being 30 (IQR: 20-55). Twenty-one children died (17.5%). Fever ( p  = 0.004), arrhythmia ( p  = 0.03), shock ( p  = 0.015), higher inotrope score ( p  = 0.0001), need for ventilation ( p  = 0.025), acidosis ( p  = 0.013), AKI ( p  = 0.0001), transaminitis ( p  = 0.0001), and multiorgan dysfunction ( p  = 0.0001) were associated with mortality. The mortality was significantly less in IVIG treated group (12.1 vs. 28.9%; p  = 0.02). On multiple logistic regression, MODS ( p  = 0.002) was independent predictor of mortality while IVIG treatment ( p  = 0.004) was favorably associated with survival. AFM complicated by multiorgan dysfunction carried a poor prognosis. IVIG was associated with survival benefit.

• Authors: Muralidharan Jayashree, Manisha Patil, Govindappa Benakatti, Manoj K Rohit, Sunit Singhi, Arun Bansal, Arun Baranwal, Karthi Nallasamy, Suresh Kumar Angurana
• Journal: Journal of pediatric intensive care (J Pediatr Intensive Care) Vol. 11 Issue 3 Pg. 215-220 (Sep 2022) ISSN: 2146-4618 [Print] Germany
• PMID: 35928042 (Publication Type: Journal Article)
• Copyright: Thieme. All rights reserved.